INT230730

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.28
First Reported 2007
Last Reported 2010
Negated 0
Speculated 0
Reported most in Body
Documents 2
Total Number 2
Disease Relevance 1.54
Pain Relevance 0.12

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

Pah (Rattus norvegicus)
Pain Link Frequency Relevance Heat
cva 9 92.20 High High
antagonist 21 5.00 Very Low Very Low Very Low
Inflammation 8 5.00 Very Low Very Low Very Low
Serotonin 6 5.00 Very Low Very Low Very Low
fluoxetine 3 5.00 Very Low Very Low Very Low
Calcium channel 3 5.00 Very Low Very Low Very Low
cytokine 3 5.00 Very Low Very Low Very Low
fibrosis 3 5.00 Very Low Very Low Very Low
aspirin 2 5.00 Very Low Very Low Very Low
withdrawal 2 5.00 Very Low Very Low Very Low
Disease Link Frequency Relevance Heat
Pulmonary Hypertension 312 100.00 Very High Very High Very High
Disease 24 94.72 High High
Cv General 3 Under Development 5 92.20 High High
Thrombosis 5 72.04 Quite High
Eisenmenger Complex 5 57.60 Quite High
Hypertrophy 37 54.12 Quite High
Systemic Sclerosis 16 37.60 Quite Low
Patent Ductus Arteriosus 1 21.52 Low Low
Ventricular Heart Septal Defects 1 20.48 Low Low
Cv General 2 Under Development 1 19.40 Low Low

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
Delayed administration of EPCs 3 weeks after MCT prevented the further progression of PAH 2 weeks later; whereas animals receiving EPCs transfected with the human eNOS gene exhibited significant regression of established disease at day 35 compared with day 21.
Negative_regulation (prevented) of Gene_expression (progression) of PAH associated with pulmonary hypertension and disease
1) Confidence 0.28 Published 2010 Journal Journal of Biomedicine and Biotechnology Section Body Doc Link PMC2843902 Disease Relevance 0.57 Pain Relevance 0
It has been postulated that in patients with CTEPH who can not undergo PEA or in whom pulmonary hypertension persists following surgery, then specific PAH therapies may be effective.
Negative_regulation (effective) of Gene_expression (therapies) of PAH associated with pulmonary hypertension
2) Confidence 0.23 Published 2007 Journal Vascular Health and Risk Management Section Body Doc Link PMC2350123 Disease Relevance 0.97 Pain Relevance 0.12

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox